Učitavanje...
Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells
The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity. Lapatinib is further associated with mitochondrial toxicity and accumulation of reactive oxygen species. The effect of lap...
Spremljeno u:
Glavni autori: | , , , |
---|---|
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
Frontiers Media S.A.
2020-06-01
|
Serija: | Frontiers in Pharmacology |
Teme: | |
Online pristup: | https://www.frontiersin.org/article/10.3389/fphar.2020.00944/full |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|